Find information on thousands of medical conditions and prescription drugs.

Glioblastoma multiforme

Glioblastoma multiforme, (GBM) also known as grade 4 astrocytoma is the most common and aggressive type of primary brain tumor, accounting for 52 percent of all primary brain tumors cases. more...

Home
Diseases
A
B
C
D
E
F
G
Galactorrhea
Galactosemia
Gardner's syndrome
Gastric Dumping Syndrome
Gastroesophageal reflux
Gaucher Disease
Gaucher's disease
Gelineau disease
Genu varum
Geographic tongue
Gerstmann syndrome
Gestational trophoblastic...
Giant axonal neuropathy
Giant cell arteritis
Giardiasis
Gigantism
Gilbert's syndrome
Gilles de la Tourette's...
Gingivitis
Gitelman syndrome
Glanzmann thrombasthenia
Glioblastoma
Glioblastoma multiforme
Glioma
Glomerulonephritis
Glossodynia
Glossophobia
Glucagonoma
Glucose 6 phosphate...
Glutaryl-CoA...
Glycogen storage disease
Glycogen storage disease...
Glycogen storage disease...
Glycogenosis type IV
Glycosuria
Goiter
Goldenhar syndrome
Goodpasture's syndrome
Graft versus host disease
Granulocytopenia
Graves' disease
Great vessels transposition
Growth hormone deficiency
Guillain-Barré syndrome
Gymnophobia
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
Medicines

Treatment can involve chemotherapy, radiotherapy and surgery. The 5 year survival rate of the disease has remained unchanged over the past 30 years, and stands at less than three percent. Even with complete resection of the tumor, combined with the best available treatment, the survival rate for GBM remains very low. Chromosomal aberrations like PTEN mutation, MDM2 mutation, and p53 mutation are commonly seen in these tumors. Growth factor aberrant signaling associated with EGFR, and PDGF are also seen. Tumors of this type may also infiltrate across the corpus callosum, producing a butterfly glioma.

Glioblastoma multiformes are characterized by the presence of small areas of necrotizing tissue that is surrounded by highly anaplastic cells. This characteristic differentiates the tumor from Grade 3 astrocytomas, which do not have necrotic tissue regions. Although glioblastoma multiforme can be formed from lower grade astrocytomas, post-mortem autopsies have revealed that most glioblastoma multiforme are not caused by previous lesions in the brain. Metastasis of GBM beyond the Central Nervous System is extremely rare.

A variant of glioblastoma multiforme is known as gliomatosis cerebri. Instead of a solid tumor, the cancerous cells are more scattered and diffuse. This variant preserves the architecture of the brain, but causes the affected portion of the brain to swell. It is extremely difficult to diagnose.

Symptoms

Although common symptoms of the disease can include seizure, headache, and hemiparesis, the single most prevalent symptom is a progressive memory, personality, or neurological deficit. The kind of symptoms produced highly depends on the location of the tumor, more so than on its pathological properties. The tumor can start producing symptoms quickly, but occasionally is asymptomatic until it reaches an enormous size. Unlike oligodendrogliomas, glioblastoma multiformes can form in either the gray matter or white matter of the brain. The symptoms can be relieved, on a primary approach, by the administration of chorticotherapy. These drugs act by rearranging the blood-brain barrier and thus reducing brain oedema. Apart from this, not many different drugs have any kind of importance on this situation. Anti-convulsants, analgesics and stomach protection drugs are usually prescribed.

A Computed Tomography (CT) or Magnetic Resonance Imaging (MRI) scan is necessary to characterize the anatomy of this tumor (size, location, heter/homogeneity). However, final diagnosis of this tumor, like most tumors, relies on histopathologic examination (biopsy examination) after biopsy or surgery.

Treatment

Treatment of primary brain tumors and brain metastases consists of both supportive and definitive therapies.

Read more at Wikipedia.org


[List your site here Free!]


New brain cancer treatment - Guilford Pharmaceuticals Inc. receives approval to use gliadel wafers to deliver drugs to treat glioblastoma multiforme cancer
From FDA Consumer, 12/1/96

A recently approved implantable wafer is the first technology to deliver an anticancer drug directly to the site of a surgically removed brain tumor in recurrent brain cancer.

Gliadel wafers were approved by FDA on Sept. 24 to treat glioblastoma multiforme, an aggressive type of brain cancer in the malignant glioma class of cancers. Glioblastoma multiforme, which occurs mainly in adults, has been extremely difficult to treat effectively with cancer therapies such as surgery, radiation, and traditional chemotherapy.

Implanted into the cavity of the brain created when a tumor is removed, the wafers--seven or eight of them, depending on the cavity's size--deliver the anticancer drug BiCNU (carmustine) directly to the affected area of the brain. The direct delivery lessens the exposure of the rest of the body to the drug.

In a study of 222 patients with recurrent malignant glioma who had been initially treated with surgery and radiation, the six-month survival rate in those with glioblastoma multiforme who received Gliadel was 56 percent, compared with 36 percent for those who received a placebo. In patients with diagnoses other than glioblastoma multiforme, Gliadel did not affect survival rates. A small 32-patient study supported these results.

Patients should be monitored closely after implantation for possible complications such as seizures, infections, abnormal wound healing, and brain swelling. Approval followed a June 15, 1996, recommendation for approval by FDA's Oncologic Drug Advisory Committee. Since October 1995, Gliadel had been available under a Treatment IND to patients with recurrent malignant glioma.

Gliadel is manufactured by Guilford Pharmaceuticals Inc., of Baltimore.

COPYRIGHT 1996 U.S. Government Printing Office
COPYRIGHT 2004 Gale Group

Return to Glioblastoma multiforme
Home Contact Resources Exchange Links ebay